GOCM
RVNC

Green Owl Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Green Owl Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-40,000
Closed -$829K – 126
2015
Q1 		$829K Buy
+40,000
New +$691K 0.63% 35

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Green Owl Capital Management's RVNC Position: Q2 2015 in Review

Green Owl Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2015, closing a stake of 40,000 shares — an estimated $829K sold.

Green Owl Capital Management first reported a position in RVNC in Q1 2015 and held it in 1 quarter. The position peaked at $829K in Q1 2015. 88 funds tracked by Wall St. Rank hold RVNC as of Q2 2015.

  • Green Owl Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Green Owl Capital Management sold 40,000 Revance Therapeutics, Inc. shares in Q2 2015, an estimated $829K.
  • Green Owl Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Green Owl Capital Management's Revance Therapeutics, Inc. position peaked at $829K in Q1 2015.
  • 88 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2015.

Based on Green Owl Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.